These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
194 related items for PubMed ID: 32059785
1. Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. Marques P, Appelman-Dijkstra NM, Gelderblom H, Kruit MC, van Furth WR, Pereira AM, Biermasz NR. Lancet Diabetes Endocrinol; 2020 Apr; 8(4):348. PubMed ID: 32059785 [No Abstract] [Full Text] [Related]
2. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. von Borstel D, A Taguibao R, A Strle N, E Burns J. Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337 [Abstract] [Full Text] [Related]
3. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab]. Gong LH, Liu WF, Ding Y, Zhang W, Yang YK, Yu F, Wong GQ, Huang XY, Niu XH. Zhonghua Bing Li Xue Za Zhi; 2018 Jun 08; 47(6):449-454. PubMed ID: 29886590 [Abstract] [Full Text] [Related]
4. The role of Denosumab in joint preservation for patients with giant cell tumour of bone. Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS. Bone Joint J; 2021 Jan 08; 103-B(1):184-191. PubMed ID: 33380180 [Abstract] [Full Text] [Related]
6. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone. Puri A, Gulia A, Hegde P, Verma V, Rekhi B. Bone Joint J; 2019 Feb 08; 101-B(2):170-177. PubMed ID: 30700112 [Abstract] [Full Text] [Related]
7. Measurement of bone mineral density as an efficacy marker in denosumab treatment of giant cell tumour of bone. Veng C, Jørgensen PH, Krog-Mikkelsen I, Stilling M. BMJ Case Rep; 2017 Oct 23; 2017():. PubMed ID: 29066635 [Abstract] [Full Text] [Related]
8. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long? Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP. Eur J Cancer; 2017 May 23; 76():118-124. PubMed ID: 28324746 [Abstract] [Full Text] [Related]
9. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series. Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R. World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843 [Abstract] [Full Text] [Related]
10. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS. Eur J Cancer; 2016 May 04; 59():1-12. PubMed ID: 26990281 [Abstract] [Full Text] [Related]
11. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience. Agarwal MG, Gundavda MK, Gupta R, Reddy R. Clin Orthop Relat Res; 2018 Sep 04; 476(9):1773-1782. PubMed ID: 30794215 [Abstract] [Full Text] [Related]
12. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Lipplaa A, Dijkstra S, Gelderblom H. Curr Opin Oncol; 2019 Jul 04; 31(4):329-335. PubMed ID: 30844887 [Abstract] [Full Text] [Related]
13. Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab. Szymczuk V, Boyce A, Merchant N. Lancet; 2023 Jul 15; 402(10397):e4. PubMed ID: 37453752 [No Abstract] [Full Text] [Related]
14. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis. Reddy K, Ramirez L, Kukreja K, Venkatramani R. J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440 [Abstract] [Full Text] [Related]
15. Giant cell tumor of bone under Denosumab treatment. Wendling D, Guillot X, Sondag M, Chaigneau L, Aubry S, Prati C. Joint Bone Spine; 2018 Jul 01; 85(4):491. PubMed ID: 28970075 [No Abstract] [Full Text] [Related]
16. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T. World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488 [Abstract] [Full Text] [Related]
17. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone]. Sørensen AL, Hansen RL, Jørgensen PH. Ugeskr Laeger; 2016 Sep 05; 178(36):. PubMed ID: 27593237 [Abstract] [Full Text] [Related]
18. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Lancet Oncol; 2019 Dec 05; 20(12):1719-1729. PubMed ID: 31704134 [Abstract] [Full Text] [Related]
19. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Eur J Surg Oncol; 2018 Sep 05; 44(9):1384-1390. PubMed ID: 29650420 [Abstract] [Full Text] [Related]